Julie Andrews Biography and Net Worth

Director of RxSight

Ms. Andrews has served as a member of our Board since August 2021, at which time she was nominated to serve as the Chairperson of the Audit Committee. Ms. Andrews has over twenty years’ experience in senior finance leadership roles with leading medical technology companies and brings a broad skill set in executing strategic initiatives and leading global finance organizations. Ms. Andrews currently serves as the Chief Financial Officer for Orthofix Medical, a leading global spine and orthopedics company. Previously, Ms. Andrews served as the Chief Financial Officer for Smart Wires Technology LTD. a clean technology company focused on digitalizing and modernizing the electrical grid from September 2021 to April 2023. From August 2019 to December 2020, Ms. Andrews held the position of Senior Vice President, Global Finance with Wright Medical Group N.V. (NASDAQ:WMGI) with responsibility for the finance, accounting, tax and treasury functions. During her time at Wright Medical, Ms. Andrews played key leadership roles in several successful mergers and acquisitions. These included leading the divestiture and carve-out of the approximately $300 million sale of the hip and knee business to Microport, providing leadership oversight for Wright Medical’s $3.3 billion in equity value acquisition of Tornier, N.V., and leading the diligence and integration planning of the sale of Wright Medical to Stryker Corporation (NYSE:SYK). Ms. Andrews was Vice President, Chief Accounting Officer from May 2012 to September 2019 of Wright Medical Group N.V. (f.k.a. Wright Medical Group Inc.). Prior to joining Wright Medical, Ms. Andrews spent fourteen years at Medtronic, Inc., (NYSE:MDT) a global medical device company. During her tenure with Medtronic, Ms. Andrews held numerous key financial positions including Vice President, Finance (Business Unit CFO) for the $3.5 billion Spine and Biologics business. Ms. Andrews began her career working with Thomas & Betts Corporation in Memphis, Tennessee and Thomas Havey, LLP in Chicago, Illinois. Ms. Andrews is currently on the board of directors of Priveterra (NASDAQ:PMGM), a healthcare focused special acquisition corporation and serves as the chair of their audit committee. Ms. Andrews received a BS in Accounting from Indiana University NW.

What is Julie Andrews' net worth?: The estimated net worth of Julie Andrews is at least $398,632.96 as of January 16th, 2025. Andrews owns 28,312 shares of RxSight stock worth more than $398,633 as of April 13th. This net worth estimate does not reflect any other investments that Andrews may own. Learn More about Julie Andrews' net worth.
How do I contact Julie Andrews?: The corporate mailing address for Andrews and other RxSight executives is , , . RxSight can also be reached via phone at 949-521-7830 and via email at ir@rxsight.com. Learn More on Julie Andrews' contact information.
Has Julie Andrews been buying or selling shares of RxSight?: Julie Andrews has not been actively trading shares of RxSight in the last ninety days. Most recently, Julie Andrews sold 15,625 shares of the business's stock in a transaction on Friday, June 14th. The shares were sold at an average price of $58.00, for a transaction totalling $906,250.00. Following the completion of the sale, the director now directly owns 30,287 shares of the company's stock, valued at $1,756,646. Learn More on Julie Andrews' trading history.
Who are RxSight's active insiders?: RxSight's insider roster includes Julie Andrews (Director), Juliet Bakker (Director), Jesse Corley (Director), Tamara Fountain (Director), Ilya Goldshleger (Insider), Ilya Goldshleger (Insider), M Kurtz (CEO), William Link (Director), Shweta Maniar (Director), Shelley Thunen (CFO), Robert Warner (Director), and Eric Weinberg (Insider). Learn More on RxSight's active insiders.
Are insiders buying or selling shares of RxSight?: In the last year, RxSight insiders bought shares 2 times. They purchased a total of 12,554 shares worth more than $549,098.81. In the last year, insiders at the sold shares 28 times. They sold a total of 160,951 shares worth more than $8,269,376.44. The most recent insider tranaction occured on March, 12th when Director Tamara Fountain sold 7,000 shares worth more than $179,970.00. Insiders at RxSight own 9.4% of the company. Learn More about insider trades at RxSight.
Information on this page was last updated on 3/12/2025.

Julie Andrews Insider Trading History at RxSight

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/14/2024	Sell	15,625	$58.00	$906,250.00	30,287

Julie Andrews Buying and Selling Activity at RxSight

RxSight Company Overview

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Today's Range

Now: $14.08

$13.50

$14.56

50 Day Range

MA: $25.63

$14.08

$34.26

2 Week Range

Now: $14.08

$13.50

$66.54

Volume

1,102,327 shs

Average Volume

603,910 shs

Market Capitalization

$570.11 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.26